2024-05-15 08:58:29 ET
Summary
- Editas Medicine shares have underperformed the S&P 500 by over 108% in the last three years.
- The company has a promising pipeline and is making strides in preclinical and clinical trials.
- However, weak financials and the risk associated with clinical trials warrant a hold decision for investors.
Investment Thesis
Editas Medicine, Inc. ( EDIT ) shares have plummeted more than 82% over the last three years underperforming the S&P 500 by more than 108%....
Read the full article on Seeking Alpha
For further details see:
Editas Medicine: Promising Milestone Achieved But Be Patient